2 results
Approved WMORecruiting
To investigate whether on demand dosing using population-based PK-models in VWD patients is reliable and feasible.
Approved WMORecruiting
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…